(Total Views: 472)
Posted On: 03/20/2020 4:18:52 PM
Post# of 72446
I just found the information below about GenOne from an October 2018 article - my earlier post stated "hydroxychloroquine is showing promising results especially when combined with an antibiotic". Could it be?
4) Can you provide a short overview of your product pipeline?
DNA-based vaccines in clinical development include those against Zika virus, the Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Hepatitis C. Our vaccines against the Severe Fever and Thrombocytopenia syndrome (SFTS) and Varicella Zoster have shown promising results in vitro pre-clinical studies.
DNA-based therapeutics in pre-clinical development include plasmid DNA-expressed Factor VIII as a prophylactic treatment for hemophilia A, Plasmid DNA-expressed monoclonal antibody for hepatitis B immunologlobulin, Plasmid DNA expressed sc4D5-VEGF-Trap for multiple oncologic targets, and plasmid DNA expressed anti-Her2 monoclonal antibody. We have shown that the plasmid DNA -expressed anti-Her2 antibody is equally or more effective in treating Her2 positive breast cancer in a xenograft mouse model of disease (Kim et al., Cancer Gene Therapy 2016; 23(10) 341–7).
GeneOne recently acquired GLS-1027, a small molecule that has been shown as active in multiple pre-clinical animal models of inflammatory and autoimmune diseases. GeneOne has also in-licensed from the University of Pennsylvania the use of quinine as a bitter taste receptor agonist for the treatment of sinus infection.
The MERS-CoV DNA vaccine moved into Phase II trials in the summer of 2018. GLS-1027 and quinine are expected to enter into Phase II trials within the next year. mRNA vaccine products are in the design phase.
4) Can you provide a short overview of your product pipeline?
DNA-based vaccines in clinical development include those against Zika virus, the Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Hepatitis C. Our vaccines against the Severe Fever and Thrombocytopenia syndrome (SFTS) and Varicella Zoster have shown promising results in vitro pre-clinical studies.
DNA-based therapeutics in pre-clinical development include plasmid DNA-expressed Factor VIII as a prophylactic treatment for hemophilia A, Plasmid DNA-expressed monoclonal antibody for hepatitis B immunologlobulin, Plasmid DNA expressed sc4D5-VEGF-Trap for multiple oncologic targets, and plasmid DNA expressed anti-Her2 monoclonal antibody. We have shown that the plasmid DNA -expressed anti-Her2 antibody is equally or more effective in treating Her2 positive breast cancer in a xenograft mouse model of disease (Kim et al., Cancer Gene Therapy 2016; 23(10) 341–7).
GeneOne recently acquired GLS-1027, a small molecule that has been shown as active in multiple pre-clinical animal models of inflammatory and autoimmune diseases. GeneOne has also in-licensed from the University of Pennsylvania the use of quinine as a bitter taste receptor agonist for the treatment of sinus infection.
The MERS-CoV DNA vaccine moved into Phase II trials in the summer of 2018. GLS-1027 and quinine are expected to enter into Phase II trials within the next year. mRNA vaccine products are in the design phase.
(0)
(0)
